• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

    1.898 +0.038 (+2.03%)
    Streaming Delayed Price Updated: 9:31 AM EST, Jan 16, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Acumen Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 12, 2025 ↗
     
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals's Earnings: A Preview ↗
     
    Via Benzinga
    News headline image
    A Preview Of Acumen Pharmaceuticals's Earnings ↗
     
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates ↗
    Acumen Pharmaceuticals posts better-than-expected Q3 2025 results, advancing its Alzheimer's treatment pipeline with cash into 2027. 
    Via Chartmill
    Topics Earnings
    News headline image
    Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Preview: Acumen Pharmaceuticals's Earnings ↗
     
    Via Benzinga
    News headline image
    Preview: Acumen Pharmaceuticals's Earnings ↗
     
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million. 
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For August 12, 2025 ↗
     
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For May 13, 2025 ↗
     
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
    Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer’s disease recently published in The Journal of Prevention of Alzheimer's Disease 
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
    Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors 
    From Climb Bio, Inc.
    Via GlobeNewswire
    News headline image
    Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday ↗
     
    Via Benzinga
    News headline image
    Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For March 27, 2025 ↗
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.